NCT02981628 2026-02-23Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaChildren's Oncology GroupPhase 2 Recruiting80 enrolled 1 FDA